Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Adani stocks led the way in Samvat 2070

Ambani brothers, JSPL the bottom three in market-cap growth

Raising the output key to Cairn India's prospects

With crude oil prices benign, increasing oil and gas production is crucial to drive growth

Biocon sees muted quarter, lacks immediate triggers

Reduced exports to West Asia & North Africa, capacity constraints affect sales

Exchanges plan stake sales in depository arms

NSE in talks with investors for offloading stake, BSE considering an IPO; to do so before April

Many listed firms had same auditors for over 10 yrs: IIAS

Proxy advisory body Institutional Investor Advisory Services India (IIAS) has called for periodic rotation of auditors and capping their tenure ...

Back to Top